Patent intelligence · US
US 11278632
Engineered nucleases useful for treatment of hemophilia A
Engineered nucleases useful for treatment of hemophilia A
Patent details — US 11278632
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 22, 2022
- Expiration
- Mar 17, 2042
- Applicant
- Precision BioSciences, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K38/00, A61K38/465, A61K48/005
Quick answer
US 11278632 (Engineered nucleases useful for treatment of hemophilia A) is held by Precision BioSciences, Inc.. Status: granted. Granted Mar 22, 2022. Expires Mar 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Precision BioSciences, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K38/00, A61K38/465, A61K48/005, A61K48/0066, A61K48/0091
More from Precision BioSciences, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233135
Therapeutic constructs for treating cancer
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 11278632?
US 11278632 (Engineered nucleases useful for treatment of hemophilia A) is held by Precision BioSciences, Inc.. Status: granted. Granted Mar 22, 2022. Expires Mar 17, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11278632?
Precision BioSciences, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 11278632 expire?
Our index shows an expiration date of Mar 17, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.